Journal
NEURO-ONCOLOGY
Volume 17, Issue -, Pages 9-14Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/nov151
Keywords
glioblastoma; immunosuppression; immunotherapy
Categories
Funding
- Dr. Marnie Rose Foundation
- National Institutes of Health [CA1208113, P50 CA127001, P30 CA016672]
Ask authors/readers for more resources
Despite maximal surgical and medical therapy, the treatment of glioblastoma remains a seriously vexing problem, with median survival well under 2 years and few long-term survivors. Targeted therapy has yet to produce significant advances in treatment of these lesions in spite of advanced molecular characterization of glioblastoma and glioblastoma cancer stem cells. Recently, immunotherapy has emerged as a promising mode for some of the hardest to treat tumors, including metastatic melanoma. Although immunotherapy has been evaluated in glioblastoma in the past with limited success, better understanding of the failures of these therapies could lead to more successful treatments in the future. Furthermore, there is a persistent challenge for the use of immune therapy to treat glioblastoma secondary to the existence of redundant mechanisms of tumor-mediated immune suppression. Here we will address these mechanisms of immunosuppression in glioblastoma and therapeutic approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available